Inhibikase Therapeutics Inc (IKT) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Inhibikase Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Inhibikase Therapeutics Inc 's ROA in the second quarter of 2026?
Inhibikase Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -40.61%.
However, within the Healthcare sector 491 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3774, from total ROA ranking in the first quarter of 2026 at 4505.
Navigating Challenges and Opportunities: Inhibikase Therapeutics Leadership Expansion Amid Financial DynamicsInhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on innovative small molecule kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH), has made significant strides recently by appointing David McIntyre as Chief Financial Officer, effective April 14, 2025. This move comes as part of a broader strategy to bolster the company s leadership team amidst notable financial milestones and the pursuit of advancing critical therapeutic developments.Despite a challenging financial climate, highlighted by a cumulative net loss of $-28 million during the 12 months ending in the fourth quarter of 2024, the company is actively positioning itself for future growth. This financial setback resulted in a concerning return on assets (ROA) of -90.02%, which stands as a stark contrast to the performance of 679 other companies within the Healthcare sector. Nevertheless, Inhibikase has shown some improvement in its ROA ranking, advancing to 3705 at the end of 2024 from a low of 4294 in the third quarter of 2024.
Inhibikase Therapeutics Expands Leadership Team Amid Significant Financial MilestonesIn an important strategic move, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the expansion of its senior leadership team, appointing two distinguished professionals who bring a wealth of experience and expertise instrumental in advancing the company’s innovative therapeutic developments. Dr. Chris Cabell has been appointed as President and Head of Research and Development, while Dr. John Adams takes on the role of Chief Scientific Officer. This leadership expansion comes at a time when Inhibikase is experiencing notable financial dynamics and active efforts toward groundbreaking research in the realm of cardiopulmonary and neurodegenerative diseases. The company has recorded a cumulative net loss of $20 million for the 12 months leading up to the third quarter of 2024. As a result, Inhibikase is currently facing a challenging return on assets (ROA) statistic of -205.59%. Nevertheless, the stock is trading 65.1% above its 52-week average, hinting at investor confidence in the company’s future directions and research potential.A focal point of Inhibikase s growth strategy is the recent announcement of a $110 million private placement financing secured on October 9, 2024. This financial boost holds critical importance as the funds are intended to propel the advancement of the company’s leading candidate, IkT-001Pro. This innovative drug is a prodrug of Imatinib, a compound significantly utilized in treating various severe diseases. The upcoming Phase 2b trial for pulmonary arterial hypertension (PAH) is particularly crucial, given the dire need for effective treatments in a market characterized by limited options. PAH is a serious condition marked by increased blood pressure in the pulmonary arteries, leading to challenging health dynamics for patients. The urgency in finding effective therapies is underscored by the significant projections behind Inhibikase’s IkT-001Pro candidate, expected to compete vigorously in the evolving landscape of PAH treatment modalities.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
